Fennec Pharmaceuticals
FENC
29 hedge funds and large institutions have $56.3M invested in Fennec Pharmaceuticals in 2020 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 5 increasing their positions, 9 reducing their positions, and 7 closing their positions.
3.33% less ownership
Funds ownership: 50.92% → 47.6% (-3.3%)
6% less funds holding
Funds holding: 31 → 29 (-2)
14% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 7
14% less capital invested
Capital invested by funds: $65.7M → $56.3M (-$9.44M)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
44% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 9
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Cadence Capital Management
Boston,
Massachusetts
|
+$959K |
| 2 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
+$456K |
| 3 |
Renaissance Technologies
New York
|
+$341K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$207K |
| 5 |
Millennium Management
New York
|
+$125K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GIM
Granahan Investment Management
Waltham,
Massachusetts
|
-$754K |
| 2 |
PP
Paloma Partners
Greenwich,
Connecticut
|
-$143K |
| 3 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$78K |
| 4 |
SCM
Solas Capital Management
Darien,
Connecticut
|
-$76.9K |
| 5 |
WQ
Wealth Quarterback
Toms River,
New Jersey
|
-$35.1K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
FDCDDQ
26
Federation des caisses Desjardins du Quebec
Levis,
Quebec, Canada
| $14 | – | – | – |
|
|
PP
27
Paloma Partners
Greenwich,
Connecticut
| – | -$143K | -22,026 | Closed |
|
|
OM
28
Opaleye Management
Boston,
Massachusetts
| – | -$78K | -12,000 | Closed |
|
29
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| – | -$9K | -1,393 | Closed |
|
|
TRCT
30
Tower Research Capital (TRC)
New York
| – | -$7K | -1,163 | Closed |
|
31
UBS Group
Zurich,
Switzerland
| – | -$6K | -983 | Closed |
|
32
Morgan Stanley
New York
| – | -$3K | -400 | Closed |
|
33
Toronto Dominion Bank
Toronto, Ontario,
Ontario, Canada
| – | -$2.08K | -319 | -93% |
|
|
PCM
34
Prelude Capital Management
New York
| – | -$2K | -244 | Closed |
|
35
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$280 | -43 | -56% |
|
FENC Hedge Fund Activity: Q1 2020 in Review
29 of the 4,538 institutional investors tracked by Wall St. Rank reported a position in Fennec Pharmaceuticals (FENC) for Q1 2020, worth a combined $56.3M — down 14% from $65.7M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of FENC and 6 opened new positions — a net loss of 1 holder — while 9 trimmed existing stakes and 5 added.
The largest buyer was Cadence Capital Management, opening a new position worth an estimated $959K. The largest seller was Granahan Investment Management, cutting an estimated $754K.
- 29 institutional investors held Fennec Pharmaceuticals (FENC) as of Q1 2020, down from 31 in Q4 2019.
- Funds reported $56.3M of Fennec Pharmaceuticals stock for Q1 2020, down 14% quarter-over-quarter.
- 6 funds opened new Fennec Pharmaceuticals positions in Q1 2020 and 7 closed out, a net change of -1 holder.
- The largest Fennec Pharmaceuticals buyer in Q1 2020 was Cadence Capital Management, an estimated $959K added.
- The largest Fennec Pharmaceuticals seller in Q1 2020 was Granahan Investment Management, an estimated $754K sold.
Based on aggregated 13F filings for Q1 2020.